
    
      STUDY OBJECTIVES

      The objective of this study is to evaluate the efficacy and safety of regorafenib at a dose
      of 120mg daily for 21 days out of every 28 day cycle in Asian females with multiply recurrent
      EOC.

      Primary Endpoint:

      Investigator assessed progression free survival (PFS)

      Secondary Endpoints:
    
  